Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs PubMatic Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while PubMatic Inc trades at $13.55 (market cap $628.84M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 63.4× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PUBM | |
|---|---|---|
Market Cap | $39.89B | $628.84M |
Sector | Health | Technology |
52-Week High | $491.22 | $13.83 |
52-Week Low | $278.09 | $6.28 |
Enterprise Value | $38.15B | $526.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
PubMatic (PUBM) trades at $13.55, showing minimal daily movement (-0.07%) with a bullish technical outlook supported by moving averages. The company reported mixed Q1 2026 results, beating EPS expectations but posting a net loss, while maintaining strong operational cash flow of $81M in 2025. Recent partnerships with Level Agency and Gracenote highlight growth in AI-powered advertising and CTV markets.
Investment outlook balances analyst optimism (50% buy ratings, $17 consensus target) against fundamental challenges including negative profit margins and elevated P/E ratio. Key risks include competitive pressure in ad tech and execution on AI initiatives, while institutional sentiment remains divided between growth potential and current profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
